Leerink Partnrs Increases Earnings Estimates for Amedisys

Amedisys, Inc. (NASDAQ:AMED) – Leerink Partnrs raised their FY2026 earnings estimates for shares of Amedisys in a research report issued to clients and investors on Wednesday, January 29th. Leerink Partnrs analyst W. Mayo now forecasts that the health services provider will earn $5.06 per share for the year, up from their prior estimate of $4.53. The consensus estimate for Amedisys’ current full-year earnings is $4.40 per share.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Wednesday, November 6th. The health services provider reported $1.00 earnings per share for the quarter, missing the consensus estimate of $1.19 by ($0.19). Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The business had revenue of $587.67 million during the quarter, compared to the consensus estimate of $586.75 million. During the same period last year, the business posted $0.98 earnings per share. The business’s revenue was up 5.7% on a year-over-year basis.

Amedisys Stock Performance

NASDAQ:AMED opened at $92.15 on Monday. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05. Amedisys has a twelve month low of $82.15 and a twelve month high of $98.95. The company has a fifty day moving average of $89.43 and a 200-day moving average of $93.92. The firm has a market capitalization of $3.02 billion, a P/E ratio of 36.57, a P/E/G ratio of 1.82 and a beta of 0.73.

Hedge Funds Weigh In On Amedisys

Several institutional investors have recently made changes to their positions in the stock. National Bank of Canada FI grew its stake in Amedisys by 119.0% in the third quarter. National Bank of Canada FI now owns 55,592 shares of the health services provider’s stock valued at $5,365,000 after acquiring an additional 30,213 shares during the period. Geode Capital Management LLC increased its stake in Amedisys by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 567,105 shares of the health services provider’s stock valued at $54,746,000 after purchasing an additional 7,071 shares in the last quarter. Quarry LP acquired a new position in Amedisys during the third quarter worth $2,569,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Amedisys by 2.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 346,082 shares of the health services provider’s stock valued at $33,400,000 after buying an additional 9,004 shares in the last quarter. Finally, Holocene Advisors LP grew its holdings in shares of Amedisys by 391.4% during the third quarter. Holocene Advisors LP now owns 79,036 shares of the health services provider’s stock valued at $7,628,000 after buying an additional 62,953 shares during the last quarter. Institutional investors and hedge funds own 94.36% of the company’s stock.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.